Activating mutations in Janus kinase 2 (JAK2) are a common feature of a number of myeloproliferative neoplasms. JAKs are also involved in the pathogenesis of inflammatory and immune-mediated disorders, and several JAK inhibitors are now in clinical development. In this Review, Quintás-Cardama and colleagues discuss the current progress in this field.
- Alfonso Quintás-Cardama
- Hagop Kantarjian
- Srdan Verstovsek
